keyword
MENU ▼
Read by QxMD icon Read
search

"glioblastoma" radiotherapy

keyword
https://www.readbyqxmd.com/read/29784026/effects-of-ionizing-radiation-on-the-viability-and-proliferative-behavior-of-the-human-glioblastoma-t98g-cell-line
#1
Hossam Murad, Yaman Alghamian, Abdulmunim Aljapawe, Ammar Madania
OBJECTIVE: Radiotherapy is the traditional therapy for glioma patients. Glioma has poor response to ionizing radiation (IR). Studying radiation-induced cell death can help in understanding the cellular mechanisms underlying its radioresistance. T98G cell line was irradiated with Co60 source by 2 or 10 Gy. MTT assay was used to calculate the surviving fraction. Cell viability, cell cycle distribution and apoptosis assays were conducted by flow cytometry for irradiated and control cells for the 10 Gy dose...
May 21, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29777390/synergistic-effect-of-trail-and-irradiation-in-elimination-of-glioblastoma-stem-like-cells
#2
Junfeng Liu, Qinglei Gao, Tao Xie, Yu Liu, Longjun Luo, Cheng Xu, Lu Shen, Feng Wan, Ting Lei, Fei Ye
Glioblastoma multiforme (GBM) is the most common malignancy in central nervous system. A small subpopulation of GBM cells known as GBM stem-like cells (GSLCs) were supposed to be the most malignant cells among GBM cells as they are resistant to multiple therapies including radiotherapy. In this study, we set up two GSLCs cell lines from the two parental U87 and U251 glioma cell lines, and studied the expression of apoptosis-related genes alteration in GSLCs before and after irradiation. We found that one of the receptors of TNF-related apoptosis-inducing ligand (TRAIL), DR5, was dramatically up-regulated in GSLCs after irradiation (IR)...
May 18, 2018: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/29774132/natural-products-a-hope-for-glioblastoma-patients
#3
REVIEW
Raghupathy Vengoji, Muzafar A Macha, Surinder K Batra, Nicole A Shonka
Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB)...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29770193/hyperbaric-oxygen-therapy-as-adjunctive-strategy-in-treatment-of-glioblastoma-multiforme
#4
REVIEW
Lei Huang, Warren Boling, John H Zhang
Glioblastoma multiforme (GBM) is the most common type of malignant intracranial tumor in adults. Tumor tissue hypoxia, high mitotic rate, and rapid tumor spread account for its poor prognosis. Hyperbaric oxygen therapy (HBOT) may improve the sensitivity of radio-chemotherapy by increasing oxygen tension within the hypoxic regions of the neoplastic tissue. This review summarizes the research of HBOT applications within the context of experimental and clinical GBM. Limited clinical trials and preclinical studies suggest that radiotherapy immediately after HBOT enhances the effects of radiotherapy in some aspects...
January 2018: Medical Gas Research
https://www.readbyqxmd.com/read/29769307/orally-bioavailable-and-blood-brain-barrier-penetrating-atm-inhibitor-az32-radiosensitizes-intracranial-gliomas-in-mice
#5
Jeremy Karlin, Jasmine Allen, Syed F Ahmad, Gareth Hughes, Victoria Sheridan, Rajesh Odedra, Paul Farrington, Elaine B Cadogan, Lucy C Riches, Antonio Garcia-Trinidad, Andrew G Thomason, Bhavika Patel, Jennifer Vincent, Alan Lau, Kurt G Pike, Thomas A Hunt, Amrita Sule, Nicholas C K Valerie, Laura Biddlestone-Thorpe, Jenna Kahn, Jason M Beckta, Nitai Mukhopadhyay, Bernard Barlaam, Sebastien L Degorce, Jason Kettle, Nicola Colclough, Joanne Wilson, Aaron Smith, Ian P Barrett, Li Zheng, Tianwei Zhang, Yingchun Wang, Kan Chen, Martin Pass, Stephen T Durant, Kristoffer Valerie
Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. A major impediment for clinical implementation is that current inhibitors have limited CNS bioavailability, thus, the goal was to identify ATM inhibitors (ATMi) with improved CNS penetration. Drug screens and refinement of lead compounds identified AZ31 and AZ32. The compounds were then tested in vivo for efficacy and impact on tumor and healthy brain...
May 16, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29767783/timing-of-radiotherapy-in-newly-diagnosed-glioblastoma-no-need-to-rush
#6
M Geurts, M J van den Bent
No abstract text is available yet for this article.
May 15, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29760590/evaluation-of-high-grade-astrocytoma-recurrence-patterns-after-radiotherapy-in-the-era-of-temozolomide-a-single-institution-experience
#7
Arno Lotar Cordova, Taynná Vernalha Rocha Almeida, Cintia Mara da Silva, Pedro Argolo Piedade, Cristiane Maria Almeida, Carlos Genesio Bezzera Lima, Carolina Dutra, Rafael Martins Ferreira, Marcelo Neves Linhares, Valeriy Denyak
Aim: Evaluating the recurrence patterns of high-grade astrocytomas in patients who were treated with radiotherapy (RT) plus temozolomide (TMZ). Background: The current literature suggests that reducing the margins added to the CTV does not significantly change the risk of recurrence and overall survival; thus, we decided to analyze our data and to examine the possibility of changing the adopted margins. Materials and methods: From February 2008 till September 2013, 55 patients were treated for high-grade astrocytomas, 20 patients who had been confirmed to have recurrence were selected for the present study...
May 2018: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/29759570/re-irradiation-as-salvage-treatment-in-recurrent-glioblastoma-a-comprehensive-literature-review-to-provide-practical-answers-to-frequently-asked-questions
#8
REVIEW
Silvia Scoccianti, Giulio Francolini, Giulio Alberto Carta, Daniela Greto, Beatrice Detti, Gabriele Simontacchi, Luca Visani, Muhammed Baki, Linda Poggesi, Pierluigi Bonomo, Monica Mangoni, Isacco Desideri, Stefania Pallotta, Lorenzo Livi
The primary aim of this review is to provide practical recommendations in terms of fractionation, dose, constraints and selection criteria to be used in the daily clinical routine. Based on the analysis of the literature reviewed, in order to keep the risk of severe side effects ≤3,5%, patients should be stratified according to the target volume. Thus, patients should be treated with different fractionation and total EQD2 (<12.5 ml: EQD2 < 65 Gy with radiosurgery; >12.5 ml and <35 ml: EQD2 < 50 Gy with hypofractionated stereotactic radiotherapy; >35 ml and <50 ml: EQD2 < 36 Gy with conventionally fractionated radiotherapy)...
June 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29753958/drug-delivery-challenges-and-future-of-chemotherapeutic-nanomedicine-for-glioblastoma-treatment
#9
REVIEW
Lakshmi Pallavi Ganipineni, Fabienne Danhier, Veronique Préat
Glioblastoma (GBM) is one of the most aggressive and deadliest central nervous system tumors, and the current standard treatment is surgery followed by radiotherapy with concurrent chemotherapy. Nevertheless, the survival period is notably low. Although ample research has been performed to develop an effective therapeutic strategy for treating GBM, the success of extending patients' survival period and quality of life is limited. This review focuses on the strategies developed to address the challenges associated with drug delivery in GBM, particularly nanomedicine...
May 10, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29750673/quality-of-life-perception-cognitive-function-and-psychological-status-in-a-real-world-population-of-glioblastoma-patients-treated-with-radiotherapy-and-temozolomide-a-single-center-prospective-study
#10
Giuseppe Lombardi, Eleonora Bergo, Paola Del Bianco, Luisa Bellu, Ardi Pambuku, Mario Caccese, Leonardo Trentin, Vittorina Zagonel
BACKGROUND: Health-related quality of life (HRQoL), cognitive function, and psychological status represent an important focus during the treatment of glioblastoma patients. Nevertheless, few randomized, prospective clinical trials have analyzed these factors, and very little is known in the real-clinical world. We evaluated these characteristics in glioblastoma patients treated with standard first-line therapy outside clinical trials. PATIENTS AND METHODS: In total, 111 newly, histologically diagnosed glioblastoma patients treated at our oncology center with radiotherapy and temozolomide were prospectively enrolled...
May 10, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29747666/survival-of-rats-bearing-advanced-intracerebral-f-98-tumors-after-glutathione-depletion-and-microbeam-radiation-therapy-conclusions-from-a-pilot-project
#11
E Schültke, E Bräuer-Krisch, H Blattmann, H Requardt, J A Laissue, G Hildebrandt
BACKGROUND: Resistance to radiotherapy is frequently encountered in patients with glioblastoma multiforme. It is caused at least partially by the high glutathione content in the tumour tissue. Therefore, the administration of the glutathione synthesis inhibitor Buthionine-SR-Sulfoximine (BSO) should increase survival time. METHODS: BSO was tested in combination with an experimental synchrotron-based treatment, microbeam radiation therapy (MRT), characterized by spatially and periodically alternating microscopic dose distribution...
May 10, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29741106/temozolomide-rechallenge-in-recurrent-glioblastoma-when-is-it-useful
#12
Enrico Franceschi, Giuseppe Lamberti, Michela Visani, Alexandro Paccapelo, Antonella Mura, Giovanni Tallini, Annalisa Pession, Dario De Biase, Santino Minichillo, Alicia Tosoni, Monica Di Battista, Alessio Cubeddu, Stefania Bartolini, Alba A Brandes
AIM: To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression. METHODS: We retrospectively evaluated 106 glioblastoma patients who had nonprogressive disease at first magnetic resonance imaging after completion of TMZ concurrent with and adjuvant to radiotherapy, a treatment-free interval (TFI) of at least 8 weeks and received TMZ rechallenge or a nitrosourea at the time of progression...
May 9, 2018: Future Oncology
https://www.readbyqxmd.com/read/29740437/targeting-and-therapy-of-glioblastoma-in-a-mouse-model-using-exosomes-derived-from-natural-killer-cells
#13
Liya Zhu, Ji Min Oh, Prakash Gangadaran, Senthilkumar Kalimuthu, Se Hwan Baek, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn
Objective: Glioblastoma is a highly aggressive primary brain tumor that is resistant to radiotherapy and chemotherapy. Natural killer (NK) cells have been used to treat incurable cancers. Recent studies have investigated the effectiveness of NK-cell-derived exosomes (NK-Exo) for treating incurable cancers such as melanoma, leukemia, and neuroblastoma; however, NK-Exo have not been used to treat glioblastoma. In the present study, we investigated the antitumor effects of NK-Exo against aggressive glioblastoma both in vitro and in vivo and determined the tumor-targeting ability of NK-Exo by performing fluorescence imaging...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29738914/g4dari-geant4-gate-based-monte-carlo-simulation-interface-for-dosimetry-calculation-in-radiotherapy
#14
Faiçal A A Slimani, Mahdjoub Hamdi, M'hamed Bentourkia
Monte Carlo (MC) simulation is widely recognized as an important technique to study the physics of particle interactions in nuclear medicine and radiation therapy. There are different codes dedicated to dosimetry applications and widely used today in research or in clinical application, such as MCNP, EGSnrc and Geant4. However, such codes made the physics easier but the programming remains a tedious task even for physicists familiar with computer programming. In this paper we report the development of a new interface GEANT4 Dose And Radiation Interactions (G4DARI) based on GEANT4 for absorbed dose calculation and for particle tracking in humans, small animals and complex phantoms...
May 1, 2018: Computerized Medical Imaging and Graphics: the Official Journal of the Computerized Medical Imaging Society
https://www.readbyqxmd.com/read/29737461/delay-in-starting-radiotherapy-due-to-neoadjuvant-therapy-does-not-worsen-survival-in-unresected-glioblastoma-patients
#15
C Balaña, A Estival, I Teruel, M Hardy-Werbin, J Sepulveda, E Pineda, M Martinez-García, O Gallego, R Luque, M Gil-Gil, C Mesia, S Del Barco, A Herrero, A Berrocal, P Perez-Segura, R De Las Penas, J Marruecos, R Fuentes, G Reynes, J M Velarde, A Cardona, E Verger, C Panciroli, S Villà
PURPOSE: We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients. PATIENTS AND METHODS: We compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy...
May 8, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29731893/cdh2-expression-is-of-prognostic-significance-in-glioma-and-predicts-the-efficacy-of-temozolomide-therapy-in-patients-with-glioblastoma
#16
Qun Chen, Jinquan Cai, Chuanlu Jiang
Glioma is the most common and malignant primary brain cancer in adults. Radical surgical excision accompanied by radiotherapy and chemotherapy is the prevailing standard therapy for patients with glioblastoma (GBM). Cadherin 2 (CDH2) encodes the N-cadherin protein, a classical cadherin and a member of the cadherin superfamily, which sustains the integrity of the cell and is involved in several cell signal transduction pathways. In the present study, the association between CDH2 expression and clinical features was investigated based on the Chinese Glioma Genome Atlas (CGGA), the Rembrandt datasets and The Cancer Genome Atlas datasets (TCGA)...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29729291/repurposing-drugs-for-glioblastoma-from-bench-to-bedside
#17
João Basso, Ana Miranda, João Sousa, Alberto Pais, Carla Vitorino
Glioblastoma multiforme is the most common, aggressive and lethal type of brain tumor. It is a stage IV cancer disease with a poor prognosis, as the current therapeutic options (surgery, radiotherapy and chemotherapy) are not able to eradicate tumor cells. The approach to treat glioblastoma has not suffered major changes over the last decade and temozolomide (TMZ) remains the mainstay for chemotherapy. However, resistance mechanisms to TMZ and other chemotherapeutic agents are becoming more frequent. The lack of effective options is a reality that may be counterbalanced by repositioning known and commonly used drugs for other diseases...
May 3, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29721752/prediction-of-survival-in-patients-affected-by-glioblastoma-histogram-analysis-of-perfusion-mri
#18
Andrea Romano, Luca Pasquini, Alberto Di Napoli, Francesca Tavanti, Alessandro Boellis, Maria Camilla Rossi Espagnet, Giuseppe Minniti, Alessandro Bozzao
PURPOSE: The identification of prognostic biomarkers plays a pivotal role in the management of glioblastoma. The aim of this study was to assess the role of magnetic resonance dynamic susceptibility contrast imaging (DSC-MRI) with histogram analysis in the prognostic evaluation of patients suffering from glioblastoma. MATERIALS AND METHODS: Sixty-eight patients with newly diagnosed pathologically verified GBM were retrospectively evaluated. All patients underwent MRI investigations, including DSC-MRI, surgical procedure and received postoperative focal radiotherapy plus daily temozolomide (TMZ), followed by adjuvant TMZ therapy...
May 2, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29713762/prolonged-survival-in-secondary-glioblastoma-following-local-injection-of-targeted-alpha-therapy-with-213-bi-substance-p-analogue
#19
Leszek Krolicki, Frank Bruchertseifer, Jolanta Kunikowska, Henryk Koziara, Bartosz Królicki, Maciej Jakuciński, Dariusz Pawlak, Christos Apostolidis, Saed Mirzadeh, Rafał Rola, Adrian Merlo, Alfred Morgenstern
BACKGROUND: Glioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently as a secondary glial neoplasm. GBM has been demonstrated to overexpress the NK-1 receptor and substance P can be used as a ligand for targeted therapy. Alpha emitters, e.g. 213 Bi, that deposit their high energy within a short range allow the selective irradiation of tumor cells while sparing adjacent neuronal structures. MATERIAL AND METHODS: Among 50 glioma patients of different subtypes that have to date been treated with targeted alpha therapy at the Medical University Warsaw, we report here the data on nine patients with secondary GBM...
April 30, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29713042/endothelial-trans-differentiation-in-glioblastoma-recurring-after-radiotherapy
#20
Ivana De Pascalis, Liliana Morgante, Simone Pacioni, Quintino Giorgio D'Alessandris, Stefano Giannetti, Maurizio Martini, Lucia Ricci-Vitiani, Matteo Malinverno, Elisabetta Dejana, Luigi M Larocca, Roberto Pallini
We hypothesized that in glioblastoma recurring after radiotherapy, a condition whereby the brain endothelium undergoes radiation-induced senescence, tumor cells with endothelial phenotype may be relevant for tumor neovascularization. Matched glioblastoma samples obtained at primary surgery and at surgery for tumor recurrence after radiotherapy, all expressing epidermal growth factor receptor variant III (EGFRvIII), were assessed by a technique that combines fluorescent in situ hybridization (FISH) for the EGFR/CEP7 chromosomal probe with immunostaining for endothelial cells (CD31) and activated pericytes (α Smooth Muscle Actin)...
April 30, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
keyword
keyword
75725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"